Madrigal advances MGL-2086 into Phase 1, adds resmetirom patents, posts Q2 2026 results

Madrigal Pharmaceuticals reported second-quarter 2026 results on July 30, 2026, highlighting progress across its MASH pipeline and commercial business. The company initiated dosing of the first healthy volunteers in a Phase 1 single ascending dose trial of MGL-2086, designed to assess safety and dose response.¹ MGL-2086 is an oral GLP-1 receptor agonist derived from orforglipron.¹ Madrigal said combining Rezdiffra with MGL-2086 could offer a best-in-disease MASH treatment in a once-daily pill.¹ The company pointed to Phase 3 MAESTRO-NASH data showing that even modest weight loss of at least 5% may enhance Rezdiffra's antifibrotic efficacy¹ as scientific rationale for the combination approach.

On the intellectual property front, the USPTO issued two new patents covering Rezdiffra's FDA-approved label, both of which have been listed in the FDA Orange Book.¹ One patent covers a weight-threshold step-down dosing regimen of 60mg or 80mg resmetirom for F2-F3 MASH patients also taking a moderate CYP2C8 inhibitor, with protection expected into 2045.¹ A second patent addresses co-administration of rosuvastatin and resmetirom, capping rosuvastatin at 20mg daily, with protection into 2042.¹ A third patent covers a method for treating well-compensated cirrhosis (F4c) with resmetirom, also expected to provide protection into 2042.¹

On commercial performance, second-quarter 2026 Rezdiffra net sales reached $364.3 million, up 71% year-over-year, with more than 49,000 patients on therapy as of June 30, 2026, more than doubling from the second quarter of 2025.¹ The company held cash, cash equivalents, restricted cash and marketable securities of $838.9 million as of June 30, 2026, compared with $988.6 million at the end of 2025.¹